Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections Seattle, Washington Feb 19-22 2023     Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)   Clinical Pharmacology at CROI 2023 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/30/23)   CROI 2023 and HIV prevention: Drs. Connie Celum and Renee Heffron - Connie Celum, MD, MPH Professor, Global Health & Medicine, Adjunct Professor Epidemiology University of Washington - Renee Heffron, PhD, MPH Professor, Department of Medicine Director, Center for AIDS Research University of Alabama at Birmingham - (04/03/23)   N6LS WITH RHUPH20 ENABLES SAFE HIGH DOSE MONOCLONAL ANTIBODY SUBCUTANEOUS DELIVERY - (09/15/23)   Impact of Baseline Factors on Virologic Response to bNAb VH3810109 (N6LS) in BANNER - (09/15/23)   LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE - (04/30/23)   Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (04/30/23)   NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR - (04/30/23)   REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR-9 AGONIST, AND BROADLY NEUTRALIZING ANTIBODIES - (04/20/23)   Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (04/20/23)   Vesatolimod Pharmacodynamic Response Associates With Time to HIV Rebound - (04/20/23)   THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL - (04/20/23)   Topics in Antiviral Medicine: early e-publication versions of our first six 2023 CROI review articles - (04/19/23)   Lenacapavir - recently published phase 2 safety/efficacy in treatment-naives; at CROI; + Preclinical Studies of New Prevention Interventions at CROI - (04/17/23)   EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (04/10/23)   MPOX IN PEOPLE LIVING WITH HIV AND CD4 COUNTS < 350 CELLS/MM3: A GLOBAL CASE SERIES - (04/10/23)   HEPATITIS DELTA INFECTION AMONG PERSONS LIVING WITH HIV - (04/10/23)   Trends in mortality in people living with HIV in an international cohort (RESPOND): comorbidities, cancer, CD4/viral load - (04/10/23)   SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV, HIV Found in Coronary Arteries of Deceased PWH - (04/03/23)   CROI Oral PrEP Session - All Modes to PrEP - (03/31/23)   A Loss of ERα Attenuates DTG-mediated Disruption of Thermogenesis in Brown Adipocytes - (03/30/23)   Weight Gain at CROI 2023 - (03/29/23)   SARCOPENIA, FRAILTY, NUTRITION AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV - (03/29/23)   COVID at CROI 2023 - (03/22/23)   Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/22/23)   THE SCIENCE OF AGING: LESSONS FOR HIV AT THE INTERFACE OF COMMONALITY AND HETEROGENEITY, George Kuchel - (03/22/23)   COMPLICATIONS Oral Abstract Session-06 at CROI 2023 - (03/22/23)   Weight Gain: Does what Goes Up Come Down ? Themed Discussion - (03/22/23)   Anal Cancer Prevention & Microbiome Biomarkers - (03/22/23)   HIV-1 Host Reservoir Reactivation after a CCR5Δ32/32 Allogeneic Hematopoietic Stem Cell Transplant - (03/22/23)   Paxlovid Reduced by 98% Hospitalization: COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT - (03/22/23)   Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/22/23)   VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA (NSV) - (03/22/23)   ADVANCES IN HIV CURE at CROI 2023, John Mellors - (03/22/23)   Predictors of Post-Switch Viremia in Patients on Injectable Cabotegravir/Rilpivirine - (03/22/23)   LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/22/23)   LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/22/23)   SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF - (03/22/23)   Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment - (03/22/23)   MICROBIOME-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION - (03/22/23)   BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)   Persistent Low Level 'Non-Suppressible' HIV Viremia - (03/22/23)   VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA - (03/22/23)   Disparities in Mpox Vaccination Uptake in San Francisco Among PLWH and People on PrEP - (03/22/23)   CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/22/23)   Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia - (03/22/23)   Persistent HIV Low-Level Viremia Can Arise From An Active Proviral Clone - (03/22/23)   Low level viremia, Nonsuppressible - (03/22/23)   REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19 - (03/22/23)   Remdesivir Retains Potent Antiviral Activity Against SARS-CoV-2 Variants of Concern - (03/22/23)   Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)   Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use in REPRIEVE - (03/20/23)   PSYCHIATRIC DISORDERS IN HIV EXPOSED UNINFECTED - VERSUS NON-HIV EXPOSED CHILDREN - (03/20/23)   HIV EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES - (03/20/23)   Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)   Academic Performance Among Children with Perinatal HIV Exposure in Botswana - (03/20/23)   PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES - (03/20/23)   Effect of in-utero HIV and ART exposure on growth during infancy - (03/20/23)   CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/20/23)   CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/16/23)   Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)   SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (03/16/23)   A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV - (03/16/23)   Any level of detectable viremia is associated with serious non-AIDS events Even Low-Level Viral Load Inflates Risk of Serious Non-AIDS Illness - (03/16/23)   Brain Aging Gap was significantly elevated in PWH compared to PWoH (p=0.001). - (03/16/23)   RACIAL AND HIV DISPARITIES IN HYPERTENSION CASCADE AMONG WOMEN - (03/14/23)   The BONDY Study: Bone density in youth living with perinatally acquired HIV - (03/14/23)   Metabolic Health and bone density in youth living with perinatal HIV - (03/14/23)   BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-A2B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION - (03/14/23)   Safety and Efficacy of Inhaled Interferon-β1a (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19 - (03/14/23)   Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)   HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA - (03/14/23)   INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS - (03/14/23)   Sofosbuvir/Velpatasvir Pharmacokinetics in Pregnant Women with Hepatitis C Virus - (03/14/23)   BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083 - (03/13/23)   Incidence of Long COVID Symptoms in Patients Previously Hospitalized With COVID-19 - (03/13/23)   Early Inflammatory Profiles Predict Maximal Disease Severity in COVID-19 - (03/13/23)   Inflammatory pathways associated with COVID-19 severity differ based on obesity status - (03/13/23)   LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR - (03/13/23)   SYNDEMIC OF CHRONIC VIRAL INFECTIONS ON THE RISK OF END-STAGE RENAL DISEASE - (03/13/23)   ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART; CD4 Matters: >500 Better - (03/12/23)   Dolutegravir exposure and congenital anomalies in sub-Saharan Africa - (03/12/23)   Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults - (03/12/23)   15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS - (03/12/23)   CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV - (03/12/23)   48 months anthropometric evolution of adolescents switching to Dolutegravir in Spain - (03/12/23)   Neurofilament light is related to cardiorespiratory and metabolic health in HIV - (03/12/23)   Weight change over 48 weeks after the transition to dolutegravir-based therapy- a prospective study in Uganda - (03/12/23)   RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO B/F/TAF (MOBETTA TRIAL) - (03/12/23)   Intramuscular cabotegravir/ rilpivirine concentrations after switching from efavirenz - (03/12/23)   Neural tube and other birth defects by HIV status and ART regimen in Eswatini - (03/12/23)   Telomere Length in Aviremic PWH: How Different is it from Persons Without HIV? - (03/07/23)   PWH Had Worse Depression Scores than PWoH & IL-6 in Men Associated with Depression - (03/07/23)   Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study - (03/07/23)   Worse Brain Aging in PWH: factors - CVD, Social Determinants, HCV, Viral Load, Unemployment - (03/07/23)   Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study - (03/07/23)   PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV - (03/07/23)   INFUSION OF CCR5 GENE-MODIFIED T CELLS PROVIDES LONG-TERM HIV CONTROL - (03/07/23)   Proportion of deaths occurring outside of health facilities that is attributable to HIV/AIDS - (03/07/23)   Pharmacokinetics and X-ray Imaging of Long-acting Cabotegravir In Situ Forming Implant - (03/07/23)   Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (03/07/23)   KAPOSI SARCOMA IN ART-TREATED PLWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS - (03/06/23)   Impact of COVID-19 and Host Factors on the Humoral Immune Repertoire in Treated HIV - (03/06/23)   Several InSTI Affect Immune Cell Mitochondrial, Proliferation and Apoptosis Ex Vivo - (03/06/23)   EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS - (03/06/23)   INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)   INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)   BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV - (03/06/23)   Comorbidities and Symptoms Associated with Falls from 2020-2021 - (03/06/23)   Internalized HIV Stigma and Mental Health/Substance Use Over Time - (03/06/23)   US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT - (03/06/23)   Mosaico (HPX3002/HVTN706) (Data as of Dec 12, 2022 as presented at a DSMB meeting on January 12, 2023) - (03/06/23)   DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19 - (03/06/23)   DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV - (03/06/23)   ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION - (03/06/23)   ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS - (03/06/23)   Estradiol concentrations in trans women on INSTIs compared to those without HIV - (03/06/23)   ORAL AND INJECTABLE PrEP USE IN THE UNITED STATES, 2013 TO 2022 - (03/05/23)   CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 - (03/05/23)   WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE? - (03/05/23)   Pre-Exposure Prophylaxis Product Choice in United States Participants in HPTN 083 - (03/05/23)   IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE - (03/05/23)   VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 5.5 YEARS OF ART - (03/05/23)   Non-AIDS Defining Malignancy Mortality In People Living With HIV; CD4 is biggest risk factor, next is smoking - (03/05/23)   Incidence of cancer among Medicaid beneficiaries with and without HIV: 2001-2015, PLWH have higher risks for certain cancers - (03/05/23)   Effects of eplerenone on myocardial perfusion and function: the Miracle HIV study: May Stall Worsening Subclinical Heart Disease With HIV - Mark Mascolini (03/05/23)   TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)   OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS - (03/05/23)   TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)   Post Covid Cognitive Impairment Neuro imaging Abnormalities on MRI- A Potential Biomarker - (03/05/23)   NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19 - (03/05/23)   Non-AIDS Cancer Risk Varies by Age in Medicaid Group With vs Without HIV - Mark Mascolini (03/03/23)   MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT - (03/03/23)   Cognitive, Motor, & Negative Valence Systems in Neurologic PASC: A Preliminary Study - (03/02/23)   EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (03/02/23)   Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV - (03/02/23)   MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE AND PHYSICAL FUNCTION IN PEOPLE WITH HIV - (03/02/23)   CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/02/23)   EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV 2nd report - (03/02/23)   (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION - (03/02/23)   Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV, Polypharmacy - (03/02/23)   Screening approaches and clinical description of the anticholinergic burden in people with HIV - (03/02/23)   TAF and Cobicistat-Boosted Drugs Tied to More Somatic Depressive Symptoms - Mark Mascolini (03/02/23)   Syringe Service Program Boosts Chances of COVID Testing in Drug Injectors - Mark Mascolini (03/02/23)   Every 10% Uptick in Masking at School Halves SARS-CoV-2 Detections - Mark Mascolini (03/02/23)   Second-Line DTG + DRV/r Controls HIV Better Than DRV/r + 2 NRTIs - Mark Mascolini (03/02/23)   Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)   Travel Strictures in Canada Slowed SARS-Cov-2 Variant Arrivals-Briefly - Mark Mascolini - (03/02/23)   CROI 2023: Lenacapavir Treatment, Prevention - (03/01/23)   CROI 2023: LA CAB/RPV Treatment, CAB Prevention Updates, New Data - (03/01/23)   Sleep disturbances are associated with cognitive function in women living with HIV - (03/01/23)   COVID-19 bivalent booster effectiveness in people with and without immune dysfunction - Mark Mascolini (03/01/23)   VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL - (03/01/23)   PRIMARY HCV INCIDENCE AMONG MSM USING PREP AND MSM WITH HIV IN NEW YORK CITY 2012-2022 - (03/01/23)   Subcutaneous Adipose Tissue Cell Composition is Associated with Visceral Fat Volume - (03/01/23)   Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in HIV - (03/01/23)   Four Distinct Biopsychosocial Phenotypes in HIV in the CHARTER Cohort-and Why They Matter - Mark Mascolini (03/01/23)   Islatravir at CROI 203: treatment, prevention, LA implant - (02/29/23)   Immune Activation Signals Similar in MSM With HIV and MSM on PrEP And Higher Than in HIV-Negative Controls - Mark Mascolini (02/29/23)   Dual-Active mAbs Better Than Single-Active Therapy in Stalling SARS-CoV-2 - Mark Mascolini (02/29/23)   LA CAB + RPV Every 4 Weeks Controls HIV in 131 of 133 With High Nonadherence Risk, Unstable Housing, Mental Illness, Homelessness, drug use - Mark Mascolini (02/29/23)   COVID in US Made HIV Diagnoses Plunge in 2020-But Why? - (02/29/23)   High Mpox Rate in MSM on PrEP, but MVA-BN Vax Stops Mpox Cold - Mark Mascolini (02/25/23)   High Mpox Rate in MSM on PrEP, but MVA-BN Vax Stops Mpox Cold - Mark Mascolini (02/25/23)   Mpox Mortality 27% if CD4s Below 100 With HIV Infection - Mark Mascolini - (02/25/23)   Cocaine Tied to White Matter Lesions With HIV, a Factor in Poor Cognitive Function - Mark Mascolini (02/25/23)   Rates of Key Death Causes With HIV Falling in Europe/America. Deaths Due to Comorbidities - Mark Mascolini - (02/25/23)   Depression or Anxiety Linked to Type 1 or 2 MI in US People With HIV - Mark Mascolini - (02/25/23)   Effects of eplerenone on myocardial perfusion and function [subclinical heart disease]: the Miracle HIV study....."may prevent worsening of subclinical heart disease in HIV" - Mark Mascolini - (02/25/23)   New Heart Disease Rate Similar With Integrase Inhibitors and Other First ART - Mark Mascolini (02/25/23)   Good Rectal TAF/EVG Levels With Rectal Inserts in HIV-Negative Men and Women - Mark Mascolini (02/25/23)   Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans - Mark Mascolini- (02/25/23)   Long-Acting Lenacapavir in a Combination Regimen for Treatment Naïve PWH: Week 80 - (02/25/23)   Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH - (02/24/23)   Lenacapavir Protects Against Rectal SHIV Acquisition in Macaque Model - (02/24/23)   Antiviral Activity of Lenacapavir Against HIV-2 Isolates - (02/24/23)   Weight and Metabolic Benefits With TDF/FTC/DTG After 4 Years of TAF/FTC+DTG - Mark Mascolini (02/24/23)   FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC - (02/24/23)   Weight Gain Among Participants Switching to a Dolutegravir-based HIV Regimen in Kenya - (02/24/23)   REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN - (02/24/23)   SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL - (02/24/23)   SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL - (02/24/23)   MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPRESSED PWH - (02/24/23)   Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection - Mark Mascolini (02/24/23)   TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection - (02/23/23)   Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting or Bictegravir/Emtricitabine/Tenofovir Alafenamide - (02/23/23)   Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting or Bictegravir/Emtricitabine/Tenofovir Alafenamide - (02/23/23)   Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (02/23/23)   ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV - (02/23/23)   HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION - (02/23/23)   Projected Benefits of Long-Acting ART (LA-ART) in PWH Viremic Not Taking Oral Therapy - (02/23/23)   EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL - (02/23/23)   Impact of integrase inhibitors on cardiovascular events in persons starting ART; INSTI did not increase CVD events in Swiss Cohort - Mark Mascolini(02/23/23)   ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING LONG-ACTING INJECTABLE CABENUVA (CABOTEGRAVIR, RILPIVIRINE) IS AS EFFECTIVE AS DAILY ORAL BIKTARVY (BIC/FTC/TAF) FOR THE TREATMENT OF HIV-1 - (02/23/23)   SOLAR (Switch Onto Long-Acting Regimen) 12-Month Results - Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (02/23/23)   LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (02/23/23)   EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS - (02/23/23)   D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE NNRTI THERAPY - (02/23/23)   Susceptibility Screening to bNAbs Teropavimab (GS-5423) and Zinlirvimab (GS-2872) in ART-Suppressed Participants - (02/23/23)   Low trough concentrations of cabotegravir and rilpivirine in patients infected with HIV switching to long-acting treatment - (02/23/23)   Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1 - (02/23/23)   8+ Year Pooled Analysis: Adherence and HIV Incidence in >6000 Women on F/TDF for PrEP - adherence matters - (02/23/23)   A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy - (02/23/23)   CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN - (02/23/23)   The LEVI Syndrome: Characteristics of early HIV infection with cabotegravir for PrEP - (02/23/23)   CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01) - (02/23/23)   Cabotegravir Pharmacology in the Background of Delayed Injections in HPTN 084 - (02/22/23)   PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)   CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)   SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)   NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)   LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)   Comparison of Telomere Length Changes Over 48 Weeks in SALSA Study: DTG/3TC vs CAR - (02/21/23)   Six-Month Outcome of F/TAF Cobicistat-Boosted Darunavir in Children 14 to < 25 kg - (02/21/23)   Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (02/21/23)   SimpliciTB Results and Hepatic Safety of Pretomanid Regimens +/- Pyrazinamide - (02/21/23)   Editorial - Shortening Tuberculosis Treatment - A Strategic Retreat - (02/21/23)   Treatment Strategy for Rifampin-Susceptible Tuberculosis - TRUNCATE-TB Trial - (02/21/23)   STANDARD VERSUS DOUBLE DOSE DOLUTEGRAVIR WITH HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS - (02/21/23)   MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN - (02/21/23)   Doxy-PEP and antimicrobial resistance in S. aureus, N. gonorrhoeae, and commensal Neisseria - (02/21/23)   Doxycycline does not prevent STIs among cisgender women - (02/21/23)   Mortality 1 Year After ICU Admission Falls Over 20 Years in HIV Group - Mark Mascolini (02/20/23)   Trends in mortality in people living with HIV in an international cohort (RESPOND). - Mark Mascolini (02/20/23)   PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION - (02/20/23)   Potential impact and efficiency of doxy-PEP among people with or at risk of HIV - (02/20/23)   One Year of Doxycycline PEP After STI May Prevent 40% of New STIs - Mark Mascolini (02/20/23)   DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN - (02/20/23)   DoxyPEP and Meningococcal Vax Keep Protecting MSM PrEP Users From STIs - Mark Mascolini (02/20/23)   ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023 - (02/14/23)   Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 - (02/14/23)